Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; and The University of Texas MD Anderson Cancer Center. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
Previous Symbol
CUSIP03116210
Phone805-447-1000
Debt
Debt-to-Equity Ratio2.05
Current Ratio3.08
Quick Ratio2.84
Price-To-Earnings
Trailing P/E Ratio15.23
Forward P/E Ratio13.45
P/E Growth2.01
Sales & Book Value
Annual Sales$22.85 billion
Price / Sales5.34
Cash Flow$15.3003 per share
Price / Cash12.52
Book Value$22.52 per share
Price / Book8.51
Profitability
EPS (Most Recent Fiscal Year)$12.58
Net Income$1.98 billion
Net Margins9.44%
Return on Equity54.14%
Return on Assets13.27%
Miscellaneous
Employees20,800
Outstanding Shares637,220,000
Market Cap$123.09 billion
OptionableOptionable
Amgen (NASDAQ:AMGN) Frequently Asked Questions
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Tuesday, October 23rd. Investors of record on Friday, November 16th will be paid a dividend of $1.32 per share on Friday, December 7th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date is Thursday, November 15th. View Amgen's Dividend History.
How will Amgen's stock buyback program work?
Amgen announced that its Board of Directors has authorized a share buyback program on Friday, February 2nd 2018, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company's leadership believes its stock is undervalued.
How were Amgen's earnings last quarter?
Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Tuesday, October, 30th. The medical research company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.45 by $0.24. The medical research company had revenue of $5.90 billion for the quarter, compared to the consensus estimate of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company's quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.27 earnings per share. View Amgen's Earnings History.
When is Amgen's next earnings date?
What guidance has Amgen issued on next quarter's earnings?
Amgen issued an update on its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of $14.00-14.25 for the period, compared to the Thomson Reuters consensus estimate of $14.03. The company issued revenue guidance of $23.2-23.5 billion, compared to the consensus revenue estimate of $23.20 billion.Amgen also updated its FY 2018 guidance to $14.00-14.25 EPS.
What price target have analysts set for AMGN?
21 brokerages have issued 1 year price targets for Amgen's stock. Their forecasts range from $179.00 to $224.00. On average, they expect Amgen's share price to reach $204.2386 in the next year. This suggests a possible upside of 6.6% from the stock's current price. View Analyst Price Targets for Amgen.
What is the consensus analysts' recommendation for Amgen?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 12 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. Cantor Fitzgerald analysts commented, ": We rate Amgen shares 12-month price target of $223. Amgen posted a nice beat and raise third quarter for top and bottom line estimates. We found Aimovig trends notable with over 100K patients on the drug. For this quarter, key products Neulasta and Enbrel are were roughly in line with consensus. New top and bottom line guidance are $23.2-23.5B and $14.00-14.25/sh. Our new top and bottom line estimates are $23.3B and $14.36/sh. Aimovig looking strong out of the gate for migraine treatment with unit demand. Aimovig sales were $22M in the quarter, but Amgen has free drug bridging programs." (10/31/2018)
- 2. Mizuho analysts commented, ". After speaking with two physicians who treat between 50-100 patients per month for cellulite to discuss the market opportunity for ENDP’s CCH, we are increasingly more positive on the market opportunity for this product, if approved. We are still maintaining our Neutral rating because we think the risk reward for ENDP’s existing business and new opportunities is already accurately reflected in its stock price. Better-than-expected Phase 3 data for CCH, a pick up in ENDP’s generics business and/or lower-than-expected calls on ENDP’s cash (debt, testosterone) would make us more positive on the stock. Please contact your Cantor Fitzgerald representative for a replay of the call." (10/26/2018)
- 3. Cann analysts commented, "The FDA approval of this sNDA for Kyprolis based on the positive A.R.R.O.W. data supports our outlook that Kyprolis will have increased adoption and greater market penetration over the next five years. The A.R.R.O.W. results support a nearly 28% increase in volume of Kyprolis administered per patient in the RRMM setting. We anticipate Kyprolis sales will increase to $2.0 billion in 2022 from $835 million in 2017 and will account for 6.2% of sales, being the fourth-largest driver of sales growth. Continuing positive data, like those demonstrated in A.R.R.O.W., ASPIRE and ENDEAVOR, along with label expansions to include overall survival in the relapsed multiple myeloma setting, support this outlook that Kyprolis will have increased adoption and greater market penetration over the next five years." (10/1/2018)
- 4. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Repatha, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the recent approval of migraine candidate, Aimovig was a huge boost. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given the slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions." (10/1/2018)
Has Amgen been receiving favorable news coverage?
Media coverage about AMGN stock has trended very negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amgen earned a daily sentiment score of -3.1 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), Regenxbio (RGNX) and Halozyme Therapeutics (HALO).
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Mr. Robert A. Bradway, Chairman & CEO (Age 55)
- Mr. David W. Meline, Exec. VP & CFO (Age 61)
- Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Dr. Sean E. Harper, Non-Exec. Officer (Age 55)
- Mr. Esteban Santos, Exec. VP of Operations (Age 50)
Who are Amgen's major shareholders?
Amgen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.10%), FMR LLC (5.62%), Bank of New York Mellon Corp (1.13%), Wells Fargo & Company MN (0.93%), LSV Asset Management (0.64%) and Bank of Montreal Can (0.36%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Institutional Ownership Trends for Amgen.
Which institutional investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Prudential Financial Inc., Bahl & Gaynor Inc., Skandinaviska Enskilda Banken AB publ , FIL Ltd, Cornerstone Wealth Management LLC, Sarasin & Partners LLP and Assenagon Asset Management S.A.. View Insider Buying and Selling for Amgen.
Which institutional investors are buying Amgen stock?
AMGN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Candriam Luxembourg S.C.A., O Shaughnessy Asset Management LLC, Bank of Montreal Can, First Trust Advisors LP, Los Angeles Capital Management & Equity Research Inc., Achmea Investment Management B.V. and Canada Pension Plan Investment Board. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $191.56.
How big of a company is Amgen?
Amgen has a market capitalization of $123.09 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.
What is Amgen's official website?
How can I contact Amgen?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]
MarketBeat Community Rating for Amgen (NASDAQ AMGN)
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
